SCM
BBIO icon

Silvant Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Silvant Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.2K Buy
+378
New +$26.5K ﹤0.01% 345
2022
Q1 		– Sell
-2,581
Closed -$43K – 334
2021
Q4 		$43K Sell
2,581
-165
-6% -$6.98K 0.01% 282
2021
Q3 		$129K Hold
2,746
– – 0.02% 210
2021
Q2 		$167K Hold
2,746
– – 0.03% 197
2021
Q1 		$169K Buy
+2,746
New +$180K 0.03% 198

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Silvant Capital Management's BBIO Position: Q2 2026 in Review

Silvant Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 378 shares worth $28.2K. The stake represents ﹤0.01% of the portfolio and ranks #345 among its holdings. This is a return to the name: Silvant Capital Management previously reported a position in BBIO as recently as Q4 2021.

Silvant Capital Management first reported a position in BBIO in Q1 2021 and has held it in 5 quarters since. The position peaked at $169K in Q1 2021. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Silvant Capital Management held 378 shares of BridgeBio Pharma worth $28.2K as of Q2 2026.
  • BridgeBio Pharma was a new Silvant Capital Management position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Silvant Capital Management's portfolio in Q2 2026, its #345 holding.
  • Silvant Capital Management first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 5 quarters since.
  • Silvant Capital Management's BridgeBio Pharma position peaked at $169K in Q1 2021.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Silvant Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.